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This brief communication focuses on aspects of a recent
case report (Yonsei Med J 2005;46:425-30) on a full and sus-
tained remission of Hodgkin's lymphoma (HL) after a single
day of chemotherapy. A septic episode required stopping
chemotherapy and starting amphotericin B and acyclovir.
Remission evidence was seen within days of starting these. A
review of research supporting the notion that amphotericin B
can reactivate latent Epstein-Barr virus and thus allow
acyclovir to kill infected HL cells is given. Experimental work
is required to confirm or refute this possibility. If successful,
amphotericin B and acyclovir treatment could be extended to
other EBV-driven cancers such as Burkitt's lymphoma,
nasopharyngeal carcinoma and the occasional EBV-related
epithelial cancer of the breast, colon, prostate, and others.
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In the June 2005 issue of the Yonsei Medical
Journal,
1 Bang et al. reported a 36-year-old male
with Hodgkins lymphoma (HL) mixed cellularity
type, stage IVB, who showed signs of regression
after a single day of COPP-AV (cyclophospha-
mide, vincristine, procarbazine, prednisone- doxo-
rubicin, vinblastine). IgM for the Epstein-Barr
virus (EBV) was negative, indicating that this HL
was not associated with recent infectious mono-
nucleosis. One day after COPP-AV, on hospital
day 16, dyspnea and X-ray evidence of bilateral
pneumonia and Candida antigenemia were noted.
Amphotericin B and acyclovir were started along
with several antibacterial antibiotics. Candida
antigenemia was indicative of immunosuppres-
sion, hence treatment initiation with acyclovir to
treat or prevent concomitant cytomegalovirus (a
Herpes virus). Acyclovir was switched to its
homologue ganciclovir. Five days after ampho-
tericin B and acyclovir/ganciclovir, A/G, treat-
ment initiation, on hospital day 21, and after mul-
tiple antibiotics, a repeat chest CT scan showed
resolving pneumonitis and smaller mediastinal
and supraclavicular lymph nodes that had been
enlarged on admission. After 2 months of hypoxic
episodes, intubation, bouts with diabetes insipitus,
pancreatitis, and peripheral neuropathy, on hos-
pital day 90, a repeat CT scan showed slight
evidence of lymphadenopathy, most areas having
resolved. Nine months later and without further
treatment, there was no evidence of HL. This
patient remains well now, 4 years later.
The sustained remission is not only astounding
itself, but also the rapidity at which it began. This
case therefore requires careful and detailed
consideration. Bang at al. conjectured that remis-
sion was a consequence of the septic episode, as
it well might have been. Cancer remission after
sepsis has a long history, which was reviewed for
the centenary of William B. Coley in 1994.
2 In the
late 1890's Coley saw remissions after iatrogeni-
cally induced erysipelas. He saw this only for
sarcomas, but these included lymphomas. Bang et
al. place their case in this category of cancer
remission induced by sepsis-triggered, massive
inflammatory mediator release and/or induction
of immunological events leading to HL cytotoxi-
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city.
An alternative explanation expounded herein, is
that the HL cells were infected with EBV. Ampho-
tericin B has profound effects on lymphocytes.
Derangements wrought by amphotericin B could
have reactivated a latent EBV infection that
entailed transcription of EBV thymidine kinase
that phosphorylates A/G, creating toxic nucleo-
side analogues that killed EBV-infected and
nearby cells.
HL is an unusual cancer for several reasons:
3
1. Only 1% of the HL tumor mass is composed
of malignant cells. The remaining 99% is
composed of non-malignant lymphocytes,
monocyte lineage cells, mast cells, eosino-
phils and fibroblasts. Such a lavish array of
non-malignant cells is quite unique.
2. The malignant HL cell, long thought to be of
cryptic origin, is now recognized to be of B
lymphocyte origin, though morphologically
deformed (several times larger, paler, less
round, with prominent nucleolus, and often
multinucleated). When a single nucleus is
present it is termed a Hodgkin cell, when
multinucleated, a Reed-Sternberg cell (together
termed HRS cells).
3. One in 10
7 to 10
9 of resting B lymphocytes in
95% of adults worldwide harbor latent EBV,
but approximately half of all HL cases have
all HRS cells infected with latent EBV (60%
in HL of mixed cellularity, as in Bang's case).
This implies that 95% of all HL cases have
HRS cells with some EBV-positive lympho-
cytes nearby in the 99% tumor mass com-
posed of non-malignant lymphocytes and
other cells.
4. Substantial numbers of non-malignant lym-
phocytes within the HL tumor mass are of
the CD4+CD25+ immunosuppressive phe-
notype, contributing to immunosuppression
seen in HL patients.
4
Herpes simplex, Herpes varicella zoster, cyto-
megalovirus, the Herpes virus causing Kaposi's
sarcoma, and EBV are all Herpes viruses and
share similar life cycle patterns and attributes
common to Herpes viruses: 1) initial transient
infection of, and active replication in, an epithe-
lium followed by 2) epigenomic residence in a
second, non-epithelium cell type (lymphocytes for
EBV and neurons for both H. simplex and H.
zoster, for example). Then, 3) low level epi-
genomic replication occurs in the secondary cell
type at the time of host cell division, assuring that
both daughter cells are infected; other than this,
infectious EBV are not produced or only mini-
mally so. This state is latent infection. 4) Infre-
quent reactivation occurs where large numbers of
complete viruses are produced. There is then full
expression of EBV-coded proteins. This is lytic
infection.
Acyclovir, famciclovir, ganciclovir, penciclovir
and valacyclovir are homologues sharing similar
anti-Herpes attributes. Ganciclovir is reviewed in
ref. 5 as representative of the group.
5 Latent
infected HRS cells do not express virally coded
thymidine kinase, and therefore A/G has little
cytotoxic effect on them until and unless active
lytic infection can be triggered when large
amounts of A/G are phosphorylated into cyto-
toxic nucleoside analogues.
Inducing lytic EBV reactivation in cancer cells
that bear latent EBV infection in order to allow
A/G to kill them is an old idea:
6
1. Feng et al.
7 suggested therapy for EBV-
positive tumors using intentional induction
of the lytic form of EBV infection combined
with ganciclovir treatment. "The addition of
ganciclovir to either gemcitabine- or doxoru-
bicin-containing chemotherapy regimens
may enhance the therapeutic efficacy of these
drugs for EBV-driven lymphoproliferative
disease ...".
2. Feng et al.
8 also showed evidence that metho-
trexate can reactivate ganciclovir phosphory-
lation activity in EBV latent infection and
suggested methotrexate in the treatment of
EBV-driven lymphoproliferative malignan-
cies as above.
3. Faller at al.
6 suggested using arginine butyr-
ate to trigger lytic reactivation with ganciclovir
to treat EBV-associated malignancies, and
showed that it can do this.
9 The butyrate
moiety is active in this regard. A butyrate
drug is already on the market in many coun-EBV Reactivation in Hodgkin's Lymphoma
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tries in the form of gamma- hydroxybutyrate
(Oxybate). It is currently approved to treat
narcolepsy but its use with A/G could be
explored for EBV treatment.
4. Daibata et al. have shown
9 that dexametha-
sone can induce ganciclovir phosphorylation
activity in EBV latently infected lymphoma
cells in vitro.
5. Empirically, COPP-AV treatment of HL in-
duces some latent infected B cells, either HRS
cells themselves or EBV-positive B cell by-
standers, to undergo EBV reactivation,
10 sug-
gesting that A/G might augment the thera-
peutic effects of current chemotherapy for
EBV-positive tumors.
6. Nasopharyngeal carcinoma is associated with
EBV infection. When grown in nude mice,
human explanted nasopharyngeal carcinoma
both shows EBV reactivation and becomes
susceptible to being killed by A/G homo-
logues.
11
Amphotericin B, used in humans for over fifty
years, is still one of the most potent anti-fungal
agents available. By preferential binding to ergos-
terol compared to cholesterol, amphotericin B
preferentially kills fungi and single cell parasites
like Leishmania spp. Amphotericin B disrupts
lymphocytes' lipid-rich rafts and functions em-
pirically as a polyclonal B cell activator, triggering
immunoglobulin synthesis and maturation-
stimuli known to trigger EBV reactivation. When
used clinically to treat fungal infection, ampho-
tericin B can cause massive inflammatory media-
tor release, in part by stimulating Toll-like re-
ceptor-2,
12,13 resulting in the activation of B
lymphocytes (including I conjecture of the HRS
cell itself).
Two related observations are of note here: 1) An
adult T cell leukemia remitted after pulmonary
and urinary tract infection.
14 Again, amphotericin
B was used over a period of many months just
prior to and during the remission. This adult T
cell leukemia relapsed fatally as a lymphoma
when amphotericin B was stopped. 2) Pseudora-
bies virus is a swine Herpes virus related to H.
simplex (and quite unrelated to rabies virus).
Augmentation of antiviral effects of acyclovir by
amphotericin B was previously noted 22 years
ago
15 in an in vitro system with pseudorabies,
further linking amphotericin B to activation of
Herpes thymidine kinase.
In conclusion, in Bang et al.'s patient, ampho-
tericin B may have reactivated latent EBV in HRS
cells, allowing A/G to kill them. Perhaps nearby
nonmalignant EBV-positive lymphocytes had their
latent EBV activated by amphotericin B and they
generated enough cytotoxic A/G metabolites to
kill the HRS clone. Components of COPP-AV
have been shown to reactivate EBV lytic infection
and may have done so, or may have contributed
to reactivation intensity. Given the safety of
amphotericin B and A/G compared to current
cytotoxic treatments like COPP-AV or irradiation,
A/G treatment of HL should be further explored
and the current hypothesis tested.
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